IONTRAC

Ion Transport Proteins in Control of Cancer Cell Behaviour

 Coordinatore WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER 

 Organization address address: SCHLOSSPLATZ 2
city: MUENSTER
postcode: 48149

contact info
Titolo: Mr.
Nome: Ingo
Cognome: Niendorf
Email: send email
Telefono: +49 251 8355881

 Nazionalità Coordinatore Germany [DE]
 Totale costo 3˙925˙580 €
 EC contributo 3˙925˙580 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2011-ITN
 Funding Scheme MC-ITN
 Anno di inizio 2011
 Periodo (anno-mese-giorno) 2011-10-01   -   2015-09-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER

 Organization address address: SCHLOSSPLATZ 2
city: MUENSTER
postcode: 48149

contact info
Titolo: Mr.
Nome: Ingo
Cognome: Niendorf
Email: send email
Telefono: +49 251 8355881

DE (MUENSTER) coordinator 608˙852.00
2 KOBENHAVNS UNIVERSITET DK participant 856˙217.00
3    UNIVERSITE DES SCIENCES ET TECHNOLOGIES DE LILLE

 Organization address address: Cité Scientifique Batiment A3
city: VILLENEUVE D'ASCQ
postcode: 59655

contact info
Titolo: Ms.
Nome: Martine
Cognome: Lecoutre
Email: send email
Telefono: +33 3 33 71 20

FR (VILLENEUVE D'ASCQ) participant 486˙063.00
4    MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.

 Organization address address: Hofgartenstrasse 8
city: MUENCHEN
postcode: 80539

contact info
Titolo: Ms.
Nome: Dagmar
Cognome: Lange
Email: send email
Telefono: +49 551 3899229
Fax: +49 551 3899451

DE (MUENCHEN) participant 462˙390.00
5    IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE

 Organization address address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD
city: LONDON
postcode: SW7 2AZ

contact info
Titolo: Ms.
Nome: Brooke
Cognome: Alasya
Email: send email
Telefono: +44 207 594 1181
Fax: +44 207 594 1418

UK (LONDON) participant 268˙551.00
6    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

 Organization address address: University Offices, Wellington Square
city: OXFORD
postcode: OX1 2JD

contact info
Titolo: Dr.
Nome: Stephen
Cognome: Conway
Email: send email
Telefono: +44 1865 289800
Fax: +44 1865 289801

UK (OXFORD) participant 268˙551.00
7    UNIVERSITA DEGLI STUDI DI FIRENZE

 Organization address address: Piazza San Marco 4
city: Florence
postcode: 50121

contact info
Titolo: Prof.
Nome: Mario
Cognome: Del Rosso
Email: send email
Telefono: +39 055 4598205
Fax: +39 055 4598900

IT (Florence) participant 254˙454.00
8    UNIVERSITA DEGLI STUDI DI BARI ALDO MORO

 Organization address address: Piazza Umberto I 1
city: BARI
postcode: 70121

contact info
Titolo: Dr.
Nome: Vito
Cognome: Tritta
Email: send email
Telefono: +39 080 544 3329
Fax: +39 080 544 3388

IT (BARI) participant 253˙112.00
9    CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL

 Organization address address: OLSHAUSENSTRASSE 40
city: KIEL
postcode: 24118

contact info
Titolo: Ms.
Nome: Susanne
Cognome: Neufeldt
Email: send email
Telefono: +49 431 880 7246
Fax: +49 431 880 1560

DE (KIEL) participant 233˙695.02
10    Bayer Pharma AG

 Organization address address: Muellerstrasse 178
city: Berlin
postcode: 13353

contact info
Titolo: Ms.
Nome: Delia
Cognome: Nölte
Email: send email
Telefono: +49 30 46812351
Fax: +49 30 46892351

DE (Berlin) participant 233˙695.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

hallmarks    hypoxia    cancers    oncology    iontrac    disease    apoptosis    rate    first    transporter    function    pancreatic    ductal    drug    cancer    diagnostic    supra    builds    transporters    underlie    disciplinary    expression    progression    survival    inter    channels    stage    transport    upon    evidence    ion    training    pathophysiology    biomarkers    proteins    cell    million    tools    animal    therapeutic    cells    pdac    adenocarcinoma   

 Obiettivo del progetto (Objective)

'With over 3 million new cases and 1.5 million arising deaths each year in Europe, cancer is a major public health problem with an urgent need for new therapies. This proposal builds upon mounting evidence that ion channels and transporters underlie many of the hallmarks of cancer. Thus, proteins involved in membrane transport, long known as important drug targets in other pathologies (channelopathies), are a new class of therapeutic and/or diagnostic targets in oncology. IonTraC is first to propose a systematic analysis of the expression, function, as well as therapeutic and diagnostic potential of proteins involved in ion transport (the 'transportome') in cancer. This paradigm will be implemented in pancreatic ductal adenocarcinoma (PDAC) which has one of the worst prognoses of all cancers, with an overall 5-year survival rate of less than 5%. IonTraC thereby provides the framework for an inter- and supra-disciplinary training for early stage researchers in a highly innovative, exponentially growing field in oncology which will have a major impact on other disciplines such as immunology and angiology as well. The main objectives of IonTraC are: • to provide a scientific and methodological platform for supra-disciplinary training of early stage researchers in and beyond the fields of ion transport and oncology • to provide an inter-sectoral training programme with special focus on career development of young researchers • to determine the concerted expression and function of ion channels and transporters required for the progression of PDAC, and • to provide validated therapeutic and diagnostic concepts and tools that are based on transport proteins serving as novel drug targets and/or biomarkers.'

Introduzione (Teaser)

European researchers are testing the novel hypothesis that proteins responsible for ion transport across cells constitute therapeutic targets for cancer.

Descrizione progetto (Article)

Pancreatic ductal adenocarcinoma (PDAC) ranks amongst the deadliest cancers, with a less than 5 % 5-year survival rate. PDAC pathophysiology is characterised by extensive connective tissue formation that eventually causes hypoxia, apoptosis resistance and metastasis.

The EU-funded 'Ion transport proteins in control of cancer cell behaviour' (IONTRAC) proposal builds upon accumulating evidence that ion channels and transporters underlie many of the hallmarks of cancer. This consortium is working to identify their therapeutic and/or diagnostic value in oncology.

Among the key activities of the IONTRAC project is the recruitment and multi-disciplinary training of fellows in clinical and experimental oncology. To facilitate research on the expression and function of ion transporters in PDAC, they optimised various cell and animal models of PDAC. A high-throughput analysis of ion transporter expression in cells lines and patient samples was completed. First indications reveal that environmental conditions such as hypoxia influence expression of these molecules.

With respect to their association with PDAC progression, primary results indicate a dependence of cancer cells on ion channels for migration and invasion. Although delineation of the precise cellular mechanism is pending, these results clearly underscore the importance of ion transporters in PDAC pathophysiology.

Studies to elucidate the therapeutic relevance of ion transporters are underway. Researchers are working on whole animal imaging to associate changes in ion transporter expression with disease progression to develop diagnostic tools. Furthermore, they are exploiting the necessity of certain channels to induce cancer cell apoptosis, and envision the design of transporter-based therapeutic strategies.

Considering that PDAC is incurable, the identification of novel biomarkers or therapeutic targets will only improve the dismal prognosis of this lethal disease.

Altri progetti dello stesso programma (FP7-PEOPLE)

PSE RETURNS (2013)

Labor-market returns to postsecondary education in Europe and the United States

Read More  

RCYCSS (2010)

Rhodium-Catalysed Ynamide Carbometallation for Stereoselective Synthesis

Read More  

HER-SFR (2011)

"Star, gas and dust in star forming regions: studying Star Formation Rate tracers at small galactic scales"

Read More